{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:45:07Z","timestamp":1791233107602,"version":"4.1.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2009,2,13]],"date-time":"2009-02-13T00:00:00Z","timestamp":1234483200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1007\/s00262-009-0673-z","type":"journal-article","created":{"date-parts":[[2009,2,12]],"date-time":"2009-02-12T14:43:08Z","timestamp":1234449788000},"page":"1647-1655","source":"Crossref","is-referenced-by-count":42,"title":["Recombinant bacillus Calmette-Gu\u00e9rin (BCG) expressing interferon-alpha 2B enhances human mononuclear cell cytotoxicity against bladder cancer cell lines in vitro"],"prefix":"10.1007","volume":"58","author":[{"given":"Wujiang","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"O\u2019Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruifa","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,2,13]]},"reference":[{"key":"673_CR1","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0022-5347(17)55282-9","volume":"124","author":"DL Lamm","year":"1980","unstructured":"Lamm DL, Thor DE, Harris SC, Reyna JA, Stogdill VD, Radwin HM (1980) Bacillus Calmette-Gu\u00e9rin immunotherapy of superficial bladder cancer. J Urol 124:38\u201340","journal-title":"J Urol"},{"key":"673_CR2","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1055-3207(18)30447-2","volume":"4","author":"MA O\u2019Donnell","year":"1995","unstructured":"O\u2019Donnell MA, DeWolf DC (1995) Bacillus Calmette-Gu\u00e9rin immunotherapy for superficial bladder cancer. New prospects for an old warhorse. Surg Oncol Clin N Am 4:189\u2013202","journal-title":"Surg Oncol Clin N Am"},{"key":"673_CR3","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/S0140-6736(98)07422-4","volume":"353","author":"AB Alexandroff","year":"1999","unstructured":"Alexandroff AB, Jackson AM, O\u2019Donnell MA, James K (1999) BCG immunotherapy of bladder cancer: 20\u00a0years on. Lancet 353:1689\u20131694","journal-title":"Lancet"},{"key":"673_CR4","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0022-5347(17)39365-5","volume":"144","author":"A Bohle","year":"1990","unstructured":"Bohle A, Gerdes J, Ulmer AJ, Hofstetter AG, Flad HD (1990) Effects of local bacillus Calmette-Gu\u00e9rin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J Urol 144:53\u201358","journal-title":"J Urol"},{"key":"673_CR5","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/S0022-5347(17)37668-1","volume":"147","author":"S Prescott","year":"1992","unstructured":"Prescott S, James K, Hargreave TB, Chisholm GD, Smyth JF (1992) Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J Urol 147:1636\u20131642","journal-title":"J Urol"},{"key":"673_CR6","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/BF00262987","volume":"17","author":"M Peuchmaur","year":"1989","unstructured":"Peuchmaur M, Benoit G, Vieillefond A, Chevalier A, Lemaigre G, Martin ED, Jardin A (1989) Analysis of mucosal bladder leucocyte subpopulations in patients treated with intravesical bacillus Calmette-Gu\u00e9rin. Urol Res 17:299\u2013303","journal-title":"Urol Res"},{"key":"673_CR7","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1046\/j.1464-410X.2001.02394.x","volume":"88","author":"F Saint","year":"2001","unstructured":"Saint F, Patard JJ, Groux Muscatelli B, Lefrere Belda MA, Diez Gil, de Medina S, Abbou CC, Chopin DK (2001) Evaluation of cellular tumor rejection mechanisms in the peritumoral bladder wall after bacillus Calmette-Gu\u00e9rin treatment. BJU Int 88:602\u2013610","journal-title":"BJU Int"},{"key":"673_CR8","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/BF01741603","volume":"33","author":"EC Boer De","year":"1991","unstructured":"De Boer EC, De Jong WH, Van Der Meijden AP, Steerenberg PA, Witjes JA, Vegt PD, Debruyne FM, Ruitenberg EJ (1991) Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette-Gu\u00e9rin. Cancer Immunol Immunother 33:411\u2013416","journal-title":"Cancer Immunol Immunother"},{"key":"673_CR9","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/BF00294021","volume":"19","author":"EC Boer De","year":"1991","unstructured":"De Boer EC, de Jong WH, van der Meijden AP, Steerenberg PA, Witjes F, Vegt PD, Debruyne FM, Ruitenberg EJ (1991) Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer. A flow cytofluorometric analysis. Urol Res 19:45\u201350","journal-title":"Urol Res"},{"key":"673_CR10","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0022-5347(17)39366-7","volume":"144","author":"A Bohle","year":"1990","unstructured":"Bohle A, Nowc C, Ulmer AJ, Musehold J, Gerdes J, Hofstetter AG, Flad HD (1990) Elevations of cytokines interleukin-1, interleukin-2 and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette-Gu\u00e9rin immunotherapy. J Urol 144:59\u201364","journal-title":"J Urol"},{"key":"673_CR11","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0022-5347(01)66424-3","volume":"155","author":"TM Reijke de","year":"1996","unstructured":"de Reijke TM, de Boer EC, Kurth KH, Schamhart DH (1996) Urinary cytokines during intravesical bacillus Calmette-Gu\u00e9rin therapy for superficial bladder cancer: processing, stability and prognostic value. J Urol 155:477\u2013482","journal-title":"J Urol"},{"key":"673_CR12","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/S0022-5347(05)66983-2","volume":"164","author":"GN Thalmann","year":"2000","unstructured":"Thalmann GN, Sermier A, Rentsch C, Mohrle K, Cecchini MG, Studer UE (2000) Urinary interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Gu\u00e9rin. J Urol 164:2129\u20132133","journal-title":"J Urol"},{"key":"673_CR13","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S0090-4295(98)00188-5","volume":"52","author":"DP Poppas","year":"1998","unstructured":"Poppas DP, Pavlovich CP, Folkman J, Voest EE, Chen X, Luster AD, O\u2019Donnell MA (1998) Intravesical bacille Calmette-Guerin induces the antiangiogenic chemokine interferon-inducible protein 10. Urology 52:268\u2013275","journal-title":"Urology"},{"key":"673_CR14","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1046\/j.1365-2249.2003.02071.x","volume":"131","author":"R Nadler","year":"2003","unstructured":"Nadler R, Luo Y, Zhao W, Ritchey JK, Austin JC, Cohen MB, O\u2019Donnell MA, Ratliff TL (2003) Interleukin 10 induced augmentation of delayed-type hypersensitivity (DTH) enhances Mycobacterium bovis bacillus Calmette-Gu\u00e9rin (BCG) mediated antitumour activity. Clin Exp Immunol 131:206\u2013216","journal-title":"Clin Exp Immunol"},{"key":"673_CR15","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/j.1365-2249.2006.03288.x","volume":"147","author":"Y Luo","year":"2007","unstructured":"Luo Y, Chen X, O\u2019Donnell MA (2007) Mycobacterium bovis bacillus Calmette-Guerin (BCG) induces human CC- and CXC-chemokines in vitro and in vivo. Clin Exp Immunol 147:370\u2013378","journal-title":"Clin Exp Immunol"},{"key":"673_CR16","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0022-5347(17)35941-4","volume":"150","author":"A B\u00f6hle","year":"1993","unstructured":"B\u00f6hle A, Thanh\u00e4user A, Ulmer AJ, Ernst M, Flad HD, Jocham D (1993) Dissecting the immunobiological effects of bacillus Calmette-Gu\u00e9rin (BCG) in vitro: evidence of a distinct BCG-activated killer (BAK) cell phenomenon. J Urol 150:1932\u20131937","journal-title":"J Urol"},{"key":"673_CR17","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/BF01520291","volume":"40","author":"A Thanh\u00e4user","year":"1995","unstructured":"Thanh\u00e4user A, B\u00f6hle A, Schneider B, Reiling N, Mattern T, Ernst M, Flad HD, Ulmer AJ (1995) The induction of bacillus-Calmette-Gu\u00e9rin-activated killer cells requires the presence of monocytes and T-helper type-1 cells. Cancer Immunol Immunother 40:103\u2013108","journal-title":"Cancer Immunol Immunother"},{"key":"673_CR18","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/BF01517042","volume":"37","author":"A Thanh\u00e4user","year":"1993","unstructured":"Thanh\u00e4user A, B\u00f6hle A, Flad HD, Ernst M, Mattern T, Ulmer AJ (1993) Induction of bacillus-Calmette-Gu\u00e9rin-activated killer cells from human peripheral blood mononuclear cells against human bladder carcinoma cell lines in vitro. Cancer Immunol Immunother 37:105\u2013111","journal-title":"Cancer Immunol Immunother"},{"issue":"Suppl 3","key":"673_CR19","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1086\/314068","volume":"31","author":"S Brandau","year":"2000","unstructured":"Brandau S, B\u00f6hle A, Thanh\u00e4user A, Ernst M, Mattern T, Ulmer AJ, Flad HD (2000) In vitro generation of bacillus Calmette-Gu\u00e9rin-activated killer cells. Clin Infect Dis 31(Suppl 3):S94\u2013S100","journal-title":"Clin Infect Dis"},{"key":"673_CR20","first-page":"3729","volume":"6","author":"S Brandau","year":"2000","unstructured":"Brandau S, Suttmann H, Riemensberger J, Seitzer U, Arnold J, Durek C, Jocham D, Flad HD, B\u00f6hle A (2000) Perforin-mediated lysis of tumor cells by Mycobacterium bovis bacillus Calmette-Gu\u00e9rin-activated killer cells. Clin Cancer Res 6:3729\u20133738","journal-title":"Clin Cancer Res"},{"key":"673_CR21","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1006\/excr.1993.1233","volume":"208","author":"KE Platts","year":"1993","unstructured":"Platts KE, Lawry J, Hancock BW, Rees RC (1993) Phenotypic and cell cycle analysis of human peripheral blood mononuclear cells activated with interleukin-2 and\/or OKT3. Exp Cell Res 208:154\u2013160","journal-title":"Exp Cell Res"},{"key":"673_CR22","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s002400050039","volume":"26","author":"JJ Patard","year":"1998","unstructured":"Patard JJ, Saint F, Velotti F, Abbou CC, Chopin DK (1998) Immune response following intravesical bacillus Calmette-Guerin instillations in superficial bladder cancer: a review. Urol Res 26:155\u2013159","journal-title":"Urol Res"},{"key":"673_CR23","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0094-0143(21)00424-9","volume":"19","author":"DL Lamm","year":"1992","unstructured":"Lamm DL (1992) Long-term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am 19:573\u2013580","journal-title":"Urol Clin North Am"},{"key":"673_CR24","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/0090-4295(91)80166-5","volume":"38","author":"R Dejager","year":"1991","unstructured":"Dejager R, Guinan P, Lamm D (1991) Long-term complete remission in bladder carcinoma in situ with intravesical tice bacillus Calmette-Gu\u00e9rin. Urology 38:507\u2013513","journal-title":"Urology"},{"key":"673_CR25","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S0022-5347(17)37316-0","volume":"147","author":"DL Lamm","year":"1992","unstructured":"Lamm DL, van der Meijden PM, Morales A, Brosman SA, Catalona WJ, Herr HW, Soloway MS, Steg A, Debruyne FM (1992) Incidence and treatment of complications of bacillus Calmette-Gu\u00e9rin intravesical therapy in superficial bladder cancer. J Urol 147:596\u2013600","journal-title":"J Urol"},{"key":"673_CR26","first-page":"257","volume":"67","author":"E Bercovich","year":"1995","unstructured":"Bercovich E, Deriu M, Manferrari F, Irianni G (1995) BCG vs. BCG plus recombinant alpha-interferon 2b in superficial tumors of the bladder. Arch Ital Urol Androl 67:257\u2013260","journal-title":"Arch Ital Urol Androl"},{"key":"673_CR27","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0090-4295(96)00375-5","volume":"48","author":"P Stricker","year":"1996","unstructured":"Stricker P, Pryor K, Nicholson T, Goldstein D, Golovsky D, Ferguson R, Nash P, Ehsman S, Rumma J, Mammen G, Penny R (1996) Bacillus Calmette-Gu\u00e9rin plus intravesical interferon alpha-2b in patients with superficial bladder cancer. Urol 48:957\u2013961","journal-title":"Urol"},{"key":"673_CR28","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.4049\/jimmunol.162.4.2399","volume":"162","author":"Y Luo","year":"1999","unstructured":"Luo Y, Chen X, Downs TM, DeWolf WC, O\u2019Donnell MA (1999) IFN-\u03b1 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Gu\u00e9rin immunotherapy. J Immunol 162:2399\u20132405","journal-title":"J Immunol"},{"key":"673_CR29","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.urolonc.2005.11.026","volume":"24","author":"FN Joudi","year":"2006","unstructured":"Joudi FN, Smith BJ, O\u2019Donnell MA, National BCG-interferon phase 2 investigator group (2006) Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urol Oncol 24:344\u2013348","journal-title":"Urol Oncol"},{"key":"673_CR30","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S1043-4666(02)00490-8","volume":"21","author":"Y Luo","year":"2003","unstructured":"Luo Y, Chen X, O\u2019Donnell MA (2003) Role of Th1 and Th2 cytokines in BCG-induced IFN-gamma production: cytokine promotion and simulation of BCG effect. Cytokine 21:17\u201326","journal-title":"Cytokine"},{"key":"673_CR31","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1365-2249.2007.03413.x","volume":"149","author":"X Chen","year":"2007","unstructured":"Chen X, O\u2019Donnell MA, Luo Y (2007) Dose-dependent synergy of Th1-stimulating cytokines on bacille Calmette-Gu\u00e9rin-induced interferon-gamma production by human mononuclear cells. Clin Exp Immunol 149:178\u2013185","journal-title":"Clin Exp Immunol"},{"key":"673_CR32","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S0022-5347(01)61832-9","volume":"161","author":"Y Zhang","year":"1999","unstructured":"Zhang Y, Khoo HE, Esuvaranathan K (1999) Effects of bacillus Calmette-Gu\u00e8rin and interferon alpha-2B on cytokine production in human bladder cancer cell lines. J Urol 161:977\u2013983","journal-title":"J Urol"},{"key":"673_CR33","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/BF01517219","volume":"41","author":"K Pryor","year":"1995","unstructured":"Pryor K, Stricker P, Russell P, Golovsky D, Penny R (1995) Antiproliferative effects of bacillus Calmette-Guerin and interferon alpha 2b on human bladder cancer cells in vitro. Cancer Immunol Immunother 41:309\u2013316","journal-title":"Cancer Immunol Immunother"},{"key":"673_CR34","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1046\/j.1365-2249.2001.01428.x","volume":"123","author":"Y Luo","year":"2001","unstructured":"Luo Y, Chen X, Han R, O\u2019Donnell MA (2001) Recombinant bacille Calmette-Gu\u00e9rin (BCG) expressing human interferon-alpha 2B demonstrates enhanced immunogenicity. Clin Exp Immunol 123:264\u2013270","journal-title":"Clin Exp Immunol"},{"key":"673_CR35","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1128\/IAI.62.6.2508-2514.1994","volume":"62","author":"MA O\u2019Donnell","year":"1994","unstructured":"O\u2019Donnell MA, Aldovini A, Duda RB, Yang H, Szilvasi A, Young RA, DeWolf WC (1994) Recombinant Mycobacterium bovis BCG secreting functional interleukin-2 enhances gamma interferon production by splenocytes. Infect Immun 62:2508\u20132514","journal-title":"Infect Immun"},{"key":"673_CR36","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1159\/000052497","volume":"39","author":"S Brandau","year":"2001","unstructured":"Brandau S, B\u00f6hle A (2001) Activation of natural killer cells by bacillus Calmette-Gu\u00e9rin. Eur Urol 39:518\u2013524","journal-title":"Eur Urol"},{"key":"673_CR37","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/1097-0215(20010601)92:5<697::AID-IJC1245>3.0.CO;2-Z","volume":"92","author":"S Brandau","year":"2001","unstructured":"Brandau S, Riemensberger J, Jacobsen M, Kemp D, Zhao W, Zhao X, Jocham D, Ratliff TL, B\u00f6hle A (2001) NK cells are essential for effective BCG immunotherapy. Int J Cancer 92:697\u2013702","journal-title":"Int J Cancer"},{"key":"673_CR38","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1097\/01.ju.0000131944.52354.63","volume":"172","author":"H Suttmann","year":"2004","unstructured":"Suttmann H, Jacobsen M, Reiss K, Jocham D, B\u00f6hle A, Brandau S (2004) Mechanisms of bacillus Calmette-Guerin mediated natural killer cell activation. J Urol 172:1490\u20131495","journal-title":"J Urol"},{"key":"673_CR39","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/j.1442-2042.2006.01697.x","volume":"14","author":"M Naoe","year":"2007","unstructured":"Naoe M, Ogawa Y, Takeshita K, Morita J, Iwamoto S, Miyazaki A, Yoshida H (2007) Bacillus Calmette-Gu\u00e9rin-pulsed dendritic cells stimulate natural killer T cells and gammadeltaT cells. Int J Urol 14:532\u2013538","journal-title":"Int J Urol"},{"key":"673_CR40","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1074-7613(01)00154-6","volume":"14","author":"CA Biron","year":"2001","unstructured":"Biron CA (2001) Interferons alpha and beta as immune regulators\u2014a new look. Immunity 14:661\u2013664","journal-title":"Immunity"},{"key":"673_CR41","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1054\/tuld.2000.0247","volume":"80","author":"S Atkinson","year":"2000","unstructured":"Atkinson S, Valadas E, Smith SM, Lukey PT, Dockrell HM (2000) Monocyte-derived macrophage cytokine responses induced by M. bovis BCG. Tuber Lung Dis 80:197\u2013207","journal-title":"Tuber Lung Dis"},{"key":"673_CR42","doi-asserted-by":"crossref","first-page":"4405","DOI":"10.1128\/IAI.65.11.4405-4410.1997","volume":"65","author":"H Matsumoto","year":"1997","unstructured":"Matsumoto H, Suzuki K, Tsuyuguchi K, Tanaka E, Amitani R, Maeda A, Yamamoto K, Sasada M, Kuze F (1997) Interleukin-12 gene expression in human monocyte-derived macrophages stimulated with Mycobacterium bovis BCG: cytokine regulation and effect of NK cells. Infect Immun 65:4405\u20134410","journal-title":"Infect Immun"},{"key":"673_CR43","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1365-2567.2004.01858.x","volume":"112","author":"S Esin","year":"2004","unstructured":"Esin S, Batoni G, Pardini M, Favilli F, Bottai D, Maisetta G, Florio W, Vanacore R, Wigzell H, Campa M (2004) Functional characterization of human natural killer cells responding to Mycobacterium bovis bacille Calmette-Guerin. Immunology 112:143\u2013152","journal-title":"Immunology"},{"key":"673_CR44","doi-asserted-by":"crossref","first-page":"10188","DOI":"10.1073\/pnas.90.21.10188","volume":"90","author":"RA Seder","year":"1993","unstructured":"Seder RA, Gazzinelli R, Sher A, Paul WE (1993) Interleukin 12 acts directly on CD4+ T cells to enhance priming for interferon-\u03b3 production and diminishes interleukin 4 inhibition of such priming. Proc Natl Acad Sci USA 90:10188\u201310192","journal-title":"Proc Natl Acad Sci USA"},{"key":"673_CR45","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1096\/fasebj.3.12.2676681","volume":"3","author":"SB Mizel","year":"1989","unstructured":"Mizel SB (1989) The interleukins. FASEB J 3:2379\u20132388","journal-title":"FASEB J"},{"issue":"Suppl 1","key":"673_CR46","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/00001813-199205000-00002","volume":"3","author":"M Alvarez-Mon","year":"1992","unstructured":"Alvarez-Mon M, Molt\u00f3 LM, Manzano L, Olivier C, Carballido JA (1992) Immunomodulatory effect of interferon-alpha 2b on natural killer cells and T lymphocytes from patients with transitional cell carcinoma of the bladder. Anticancer Drugs 3(Suppl 1):5\u20138","journal-title":"Anticancer Drugs"},{"key":"673_CR47","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1038\/bjc.1994.481","volume":"70","author":"L Molt\u00f3","year":"1994","unstructured":"Molt\u00f3 L, Alvarez-Mon M, Carballido J, Manzano L, Guillen C, Prieto A, Olivier C, Rodriguez-Zapata M (1994) Intracavitary prophylactic treatment with interferon alpha 2b of patients with superficial bladder cancer is associated with a systemic T-cell activation. Br J Cancer 70:1247\u20131251","journal-title":"Br J Cancer"},{"key":"673_CR48","first-page":"611","volume":"19","author":"DN Mitropoulos","year":"2005","unstructured":"Mitropoulos DN (2005) Novel insights into the mechanism of action of intravesical immunomodulators. In Vivo 19:611\u2013621","journal-title":"In Vivo"},{"key":"673_CR49","first-page":"2726","volume":"5","author":"JW Slaton","year":"1999","unstructured":"Slaton JW, Perrotte P, Inoue K, Dinney CP, Fidler IJ (1999) Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res 5:2726\u20132734","journal-title":"Clin Cancer Res"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-009-0673-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-009-0673-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-009-0673-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T00:14:08Z","timestamp":1684887248000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-009-0673-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2,13]]},"references-count":49,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["673"],"URL":"https:\/\/doi.org\/10.1007\/s00262-009-0673-z","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,2,13]]}}}